Literature DB >> 15947302

Nitrosative stress, heme oxygenase-1 expression and airway inflammation during severe exacerbations of COPD.

Maria Tsoumakidou1, Nikolaos Tzanakis, Georgios Chrysofakis, Nikolaos M Siafakas.   

Abstract

STUDY
OBJECTIVES: The aim of this study was to examine the relationship between airway inflammation, nitrosative stress, heme-oxygenase expression, and acute severe exacerbations of COPD.
DESIGN: We measured heme oxygenase (HO)-1, inducible nitric oxide (NO) synthase expression and nitrotyrosine formation, as well as eosinophilic cationic protein, myeloperoxidase (MPO), interleukin (IL-8), and granulocyte macrophage-colony stimulating factor levels in induced sputum samples from 12 COPD patients (mean +/- SD; FEV1 40 +/- 14% predicted) at the onset of an acute severe exacerbation of COPD requiring hospital admission and 16 weeks after remission.
RESULTS: We demonstrated increased percentages (p = 0.001) and absolute numbers (p = 0.028) of total nitrotyrosine positive (+ve) inflammatory cells (ie, polymorphonuclear cells and macrophages), increased percentages (p = 0.04) and absolute numbers (p = 0.05) of total HO-1 +ve inflammatory cells, and increased MPO (p = 0.005) and IL-8 levels (p = 0.028) during severe exacerbation compared with the stable state.
CONCLUSIONS: Our results support the hypothesis of an involvement of inflammatory and nitrosative stress in severe COPD exacerbations. Future therapeutic strategies may aim at regulating inflammation and NO synthesis during COPD exacerbations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15947302     DOI: 10.1378/chest.127.6.1911

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  22 in total

1.  Exposing rodents to a combination of tobacco smoke and lipopolysaccharide results in an exaggerated inflammatory response in the lung.

Authors:  E L Hardaker; M S Freeman; N Dale; P Bahra; F Raza; K H Banner; C Poll
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  Biomarkers of systemic inflammation in stable and exacerbation phases of COPD.

Authors:  Fisun Karadag; Aslihan B Karul; Orhan Cildag; Mustafa Yilmaz; Hatice Ozcan
Journal:  Lung       Date:  2008-09-20       Impact factor: 2.584

3.  Biological monitoring of particulate matter accumulated in the lungs of urban asthmatic children in the Tel-Aviv area.

Authors:  Elizabeth Fireman; Daria Bliznuk; Yehuda Schwarz; Ruth Soferman; Shmuel Kivity
Journal:  Int Arch Occup Environ Health       Date:  2014-08-20       Impact factor: 3.015

4.  Granulocyte-macrophage colony-stimulating factor expression in induced sputum and bronchial mucosa in asthma and COPD.

Authors:  S Saha; C Doe; V Mistry; S Siddiqui; D Parker; M Sleeman; E S Cohen; C E Brightling
Journal:  Thorax       Date:  2009-02-12       Impact factor: 9.139

5.  Disrupted postnatal lung development in heme oxygenase-1 deficient mice.

Authors:  Tiangang Zhuang; Monica Zhang; Huayan Zhang; Phyllis A Dennery; Qing S Lin
Journal:  Respir Res       Date:  2010-10-10

Review 6.  Carbon monoxide in exhaled breath testing and therapeutics.

Authors:  Stefan W Ryter; Augustine M K Choi
Journal:  J Breath Res       Date:  2013-02-27       Impact factor: 3.262

Review 7.  Pathogen-directed therapy in acute exacerbations of chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez
Journal:  Proc Am Thorac Soc       Date:  2007-12

Review 8.  Role of macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; Jeffrey L Curtis; Richard Albert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

Review 9.  Apoptotic mechanisms in the pathogenesis of COPD.

Authors:  Maria Plataki; Eleni Tzortzaki; Paula Rytila; Makris Demosthenes; Anastassios Koutsopoulos; Nikolaos M Siafakas
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

10.  Differential expression analysis for pathways.

Authors:  Winston A Haynes; Roger Higdon; Larissa Stanberry; Dwayne Collins; Eugene Kolker
Journal:  PLoS Comput Biol       Date:  2013-03-14       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.